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ABSTRACT
Introduction: Anti-diabetes medication
regimen adherence is a clinical challenge in
elderly patients with type 2 diabetes (T2D) and
other comorbidities associated with aging.
Glucagon-like peptide-1 receptor agonists
(GLP-1RA) therapies such as exenatide once
weekly (QW), exenatide twice daily (BID), and
liraglutide once daily (QD) are an increasingly
used class of drugs with proven efficacy and
tolerability. Real-world evidence on adherence
to GLP-1RAs in elderly or disabled patients is
limited. To further the understanding of this
drug class, the current study examined
medication adherence in Medicare patients
aged C65 years with T2D initiating a GLP-1RA.
Methods: This retrospective cohort study used
medical and pharmacy claims between 2010
and 2013 for Medicare members in a United
States health plan diagnosed with T2D who
were new initiators of either exenatide QW
(n = 537), exenatide BID (n = 923), or
liraglutide QD (n = 3,673). Included patients
were between the ages of 65 and 89 and were
continuously enrolled for 6 months pre- and
post-index. Medication adherence was
examined during the post-index period using
proportion of days covered (PDC) C80% and
C90%.
Results: A significantly higher percentage of
patients receiving exenatide QW had a PDC
C80% (43.2%) versus exenatide BID (39.0%,
P\0.01) and liraglutide QD (35.0%, P\0.001).
The patients receiving exenatide QW were
significantly more likely to reach a PDC of
C90% (37.2%, P\0.001) than those initiating
exenatide BID (20.6%) or liraglutide QD
(23.3%).
Conclusions: While results from this
retrospective study suggest room for
improvement in adherence to GLP-1RAs,
medication adherence rates for patients
initiating therapy with exenatide QW were
higher than patients initiating therapy with
exenatide BID or liraglutide QD. Further
research is needed to validate these findings in
other T2D patient populations.
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INTRODUCTION
Diabetes currently affects 29.1 million, or 9.3%,
of the United States (US) population, and a
nearly equal percentage of individuals
worldwide [1]. Type 2 diabetes (T2D) accounts
for approximately 90–95% of all diabetes cases
and is associated with significant morbidity and
mortality, is the leading cause of kidney failure,
heart disease, and stroke, and is the seventh
leading cause of death in the US. The high
prevalence of the disease in the US has led to
continually rising costs [2]. In fact, the
American Diabetes Association estimated that
diabetes costs in the US are approximately
US$245 billion annually [2].
More than one-quarter or 25% of adults
65 years and older have diabetes, and
approximately 95% of these patients have T2D
[3]. As these patients grow older, the social
economic impact and personal burden of their
disease will increase [4, 5]. A study examining
this growing burden in the elderly found that
from 1994 to 2004 the incidence and prevalence
of diabetes increased by 23% and 62%,
respectively; as expected, increases in
comorbid complications such as congestive
heart failure, hypertension and renal events
were also found [1, 4]. While elderly patients
with diabetes are at risk for comorbid
conditions similar to their younger
counterparts, they are also at a high risk for
other geriatric comorbid conditions such as
cognitive impairment and depression [5, 6]. As
the size of the elderly population is expected to
grow in the future, the prevalence of diabetes in
the US and worldwide will also likely continue
to rise in parallel [7].
Because of the increased risk of
geriatric-related comorbid conditions, treating
T2D in elderly patients is at times difficult [8, 9].
As with all patients with diabetes, one of the
main treatment objectives is managing glucose
control [10]. As initial therapy, increased
exercise and dietary changes may be
recommended; however, in elderly patients
with T2D, lifestyle changes may not be
sufficient [11]. There are oral anti-diabetes
treatments available such as metformin,
sulfonylureas, alpha glucosidase inhibitors,
sodium-glucose transporter-2 inhibitors,
dipeptidyl-peptidase-4 inhibitors (DPP-4i), or
thiazolidinediones (TZDs). These therapies
have shown beneficial effects, but
monotherapy often does not have sustained
benefits. Because of the progression of diabetes,
especially in the older adult population,
polypharmacy may be required and can carry
an increased risk for adverse events [11].
In recent years, incretin-based therapy, such
as treatment with glucagon-like peptide-1
receptor agonists (GLP-1RAs), has attracted
interest as a novel therapeutic alternative for
all patients with T2D, particularly elderly
patients with T2D. GLP-1RAs such as
Bydureon [exenatide extended-release (QW)
for injectable suspension], Byetta [exenatide
twice-daily (BID) injection], and Victoza
[liraglutide (QD) (rDNA origin) injection] are
indicated as adjunct therapy to diet and exercise
to improve glycemic control in adults with T2D
[12–14]. These glucose-lowering therapies
improve insulin secretion and sensitivity,
reduce glycosylated hemoglobin levels,
suppress inappropriate glucagon secretion,
slow gastric emptying, and reduce food intake
by increasing satiety [8, 9, 15, 16]. GLP-1RA
therapies could also be associated with a lower
risk of cardiovascular disease events and
hospitalizations [17].
Adherence to these therapies is an important
modifiable factor when considering the
treatment complexity of this disease,
particularly in elderly patients (age 65 and
older). Currently, there is limited real-world
data regarding adherence to GLP-1RAs for
Medicare patients with T2D; however, there is
some evidence in commercially insured patients
[18, 19]. One 6-month retrospective database
study of adult patients with T2D from a large
commercial health plan suggested that patients
initiating treatment with exenatide QW were
more likely to be adherent than patients
initiating treatment with exenatide BID and
liraglutide QD [20]. Another study examining
the same commercial database found that
patients receiving exenatide QW had lower
all-cause medical costs compared with
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liraglutide QD 6 months following treatment
initiation [18].
The value of exenatide QW in comparison to
other GLP-1RAs can be established based on
comparative efficacy data. Because older adult
patients with diabetes are at a higher risk for
increased resource utilization such as
hospitalizations [21], understanding adherence
to these newer therapies in an aging population
is crucial for reducing morbidity, mortality, and




Data for this study were procured from the
Humana administrative claims database.
Medical and pharmacy claims with a service
date between July 1, 2009 and August 31, 2014
for the Medicare population were extracted. The
data sources for this study included patient
enrollment and medical and pharmacy claims.
Enrollment data included patient demographics
such as age, gender, and geographical region.
Medical claims data included diagnosis codes
based on the International Classification of
Diseases, Ninth Revision, Clinical
Modifications (ICD-9-CM) associated with
medical encounters and financial information.
Pharmacy claims included fill dates for
prescriptions, national drug codes (NDC), and
drug cost data. The study protocol was
submitted to and approved by an institutional
review board (IRB), Schulman Associates IRB,
prior to study initiation. This article does not
contain any new studies with human or animal
subjects performed by any of the authors.
Patient and Cohort Selection
Three cohorts of patients were identified based
on medical diagnosis and the type of GLP-1RA
they were prescribed, exenatide QW, exenatide
BID, or liraglutide QD, between January 1, 2010
and February 28, 2014. The first fill date for a
GLP-1RA was considered the index date. All the
identified patients were required to be
treatment-naı¨ve, and new initiators to
GLP-1RA therapy were defined as no evidence
of any GLP-1RA prescription during the
6-month baseline period. The liraglutide QD
cohort was further split based on the dosage
patients received at index, which was either
1.2 mg or 1.8 mg.
Patients were required to have C1 medical
claim for T2D during the observation period,
defined as C1 inpatient or C2 outpatient
medical claims with an ICD-9-CM of 250.x0 or
250.x2 at any time during the observation
period. Patients were also required to have
been enrolled for both medical and pharmacy
benefits and continuously enrolled for
6 months pre- and post-index. Finally, patients
were required to be between the ages of 65 and
89, calculated at the index date. Patients were
excluded from any of the cohorts if they had a
diagnosis of pregnancy, gestational diabetes, or
type 1 diabetes (T1D) during the observation
period, pharmacy claims for C2 GLP-1RAs on
the index date, or any GLP-1RA utilization
during the baseline period. Five cohorts were
created to be used in further analyses: exenatide
QW, exenatide BID, liraglutide QD (all patients
treated with liraglutide QD at index, regardless
of dosage), liraglutide QD 1.2 mg and liraglutide
QD 1.8 mg.
Figure 1 displays the selection criteria used to
identify the study cohorts and the final attrition
counts for each. A total of 11,956 patients had
C1 claims during the identification period for
one of the GLP-1RAs. After applying all
inclusion and exclusion criteria, a total of
5133 patients were included and divided into
the final study cohorts. Final sample sizes for
each cohort were as follows: exenatide
QW = 537, exenatide BID = 923, liraglutide
QD = 3673, liraglutide QD 1.2 mg = 1980 and
liraglutide QD 1.8 mg = 1693.
Study Measures
Demographic and Clinical Characteristics
Demographic and clinical characteristics were
evaluated for patients in all cohorts for the
6-month baseline period. Demographic
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characteristics included age, gender, race/
ethnicity, geographical region, as well as plan
type [e.g., health maintenance organization
(HMO) and preferred provider organization
(PPO)], prescriber specialty, and the number of
patients who filled their index prescription at a
retail pharmacy. Several clinical characteristics
and indices of general health and resource use
were also examined. The clinical characteristics
consisted of the Deyo–Charlson Comorbidity
Index (DCCI) and 8 additional comorbid
conditions: microvascular complications of
diabetes, cardiovascular disease, dyslipidemia,
hypertension, hypoglycemia, obesity, renal
impairment, and endocrinologist visits. Indices
of general health and resource use consisted of
mean total baseline healthcare costs and the
number of inpatient admissions during the
baseline period. All-cause hospitalizations
consisted of inpatient stays.
Other anti-diabetes medication classes taken
prior to the initiation of any GLP-1RA were
Fig. 1 Attrition counts for ﬁnal GLP-1RA cohorts. Final
counts attained by applying all inclusion and exclusion
criteria. BID Twice daily, GLP-1RA glucagon-like
peptide-1 receptor agonist, QD once daily, QW once
weekly, T1D type 1 diabetes, T2D type 2 diabetes
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tracked and assessed. The 10 medication classes
were alpha-glucose inhibitors, biguanides,
DPP-4i, dopamine receptor agonists,
meglitinides, sulfonylureas, TZD, insulins,
amylin analogues, and fixed dose
combinations. The mean number of other
anti-diabetes medication classes taken by
patients in each cohort was also recorded.
Index Dose and Refill Rates
Index dose was evaluated using the specific
GLP-1RA being prescribed to ensure the dose
was captured and used the quantity and
duration commonly available on pharmacy
claims. A weekly index dose was calculated for
the exenatide QW cohort and a daily index dose
was calculated for the exenatide BID and
liraglutide QD cohorts and sub-cohorts. For
each calculation, the Drug Strength and
Package Size were determined from the NDC
on the claim for each of the GLP-1RAs. The
Days’ supply and metric quantity on the index
GLP-1RA claim were also recorded. The
following are the computations used to
determine the index dose for each of the
cohorts:
exenatide QW:
Weekly dose mg=weekð Þ
¼ Drug Strength  Package Sizeð
 Metric Quantity  7Þ = Days of Supply
exenatide BID:
Daily dose mcg=dayð Þ
¼ Drug Strength  Package Sizeð
 Metric QuantityÞ = Days of Supply
liraglutide QD:
Daily dose mg=dayð Þ
¼ Drug Strength  Package Sizeð
 Metric QuantityÞ = Days of Supply
The refill rate was computed as the number
of times the patients obtained a refill for the
index therapy. A 90-day fill was counted as 3
refills (3 9 30 days). An original fill consisting of
a 90-day fill was counted as 2 refills (original fill
for 30 days ? 2 9 30 day refills). Given the
length of the post-index period, the maximum
number of refills was right-censored at a total of
5 refills. Index dose, daily dose, and refill rates
were examined for the 6-month period after the
index date.
GLP-1RA Medication Adherence
Adherence was measured using the proportion
of days covered (PDC) measure. The Pharmacy
Quality Alliance considers patients adherent to
their therapy if they have fills for the target
therapies for 80% of the examined post-index
period. Adherence results were calculated for
patients with T2D who reached a PDC of C80%
or a PDC of C90% [19]. This measure was
computed by chaining all the fill dates for the
target therapy and counting the number of days
for which the appropriate dose of the therapy
was available during the post-index period. The
Leslie method was used to calculate PDC [22].
The mean PDC was also calculated for each of
the cohorts in the study.
Post-Index Hospitalization
All-cause hospitalizations were identified during
the post-index period using claims data. A
hospitalization consisted of a claim associated
with a hospital as a place of service and lasting
for at least one overnight stay as measured by
admit and discharge dates. Both elements are
required to be considered a valid
hospitalization.
Statistical Analyses
All analyses were conducted using SAS v.9.3.
The a priori alpha level for analyses was set at
0.05, and subjected to the Holm adjustment to
compensate for each pair of contrasts, and all
statistical tests were two-tailed unless otherwise
specified. For the demographic and clinical
characteristics, means and standard deviations
were calculated for continuous variables. For
any categorical variables, counts and
percentages were calculated. For the
demographic and clinical characteristics,
comparisons between the cohorts were
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conducted using t tests for all continuous
variable data and Chi square tests for all
categorical data.
To minimize the risk of selection bias for the
cohorts before computing any outcome
measures, inverse propensity treatment score
weighting (IPTW) was employed [23]. This
method uses propensity scores, but is designed
to maintain the sample size of each cohort. A
propensity score is a conditional probability of
each patient receiving a particular treatment
based on pretreatment variables. The inverse
propensity treatment weight is then generated
in two steps. First, the inverse of the propensity
score is calculated for all individuals (1/
propensity score), then the weight is adjusted
to size of each cohort. The success of the
matching is determined by re-testing for
differences among the same co-variates tested
prior to matching. Successful matching is
determined by establishing that the cohorts do
not differ. The resulting IPT weights are then
carried forward for all remaining analyses. Age,
gender, DCCI and other comorbid conditions,
geographic regions and other anti-diabetes
medication classes were used in matching.
However, prior to matching the liraglutide
QD, liraglutide QD sub-cohorts and the
exenatide BID cohorts to the exenatide QW
cohort, the existence of significant differences
between the cohort pairings on the clinical and
demographic characteristics were tested using
two-sample Chi square tests for the categorical
variables and two sample t tests for the
continuous variables.
Additionally, the index treatment of other
anti-diabetes medication classes was computed
for each cohort. The exenatide BID, liraglutide
QD, liraglutide QD 1.2 mg and liraglutide QD
1.8 mg cohorts were then contrasted with the
exenatide QW cohort to further describe
potential differences between these cohorts. To
calculate the adherence rate, a logistic model
was generated to determine which factors may
be associated with variation in adherence rates.
A series of logistic regression models were
performed to predict the likelihood of patients
being adherent to their GLP-1RA or being
hospitalized following the initiation of a
GLP-1RA. The first regression model was
generated to determine which patients were
more likely to be adherent during the 6-month
follow-up period. A second logistic regression
model was generated to determine the risk of
hospitalization (all-cause inpatient stays) for
patients during the 6-month follow-up period.
Both models included the following covariates:
age, gender, geographical region, race/ethnicity,
plan type, prescriber specialty, DCCI overall
score, the eight additional comorbid conditions
listed above, and all T2D treatments. The
exenatide QW cohort was used as the
reference group for both logistic regression
models. All resulting statistical tests from these
analyses consisted of logistic regression
estimates, significance level and a likelihood
score (% likelihood adherent or
hospitalization).
Furthermore, a series of statistical tests
comparing the matched cohorts were
performed. For continuous variables other
than patient counts, a series of pairwise t tests
were performed to determine if there were
significant differences between the cohorts.
For categorical variables, Chi square tests
(Fischer’s exact test) for two samples were
performed on the matched data.
RESULTS
GLP-1RA Cohort Populations
All analyses for the demographic and clinical
characteristics were completed prior to the
IPTW adjustment. Table 1 reports the
unadjusted results for all demographic and
clinical characteristics for all cohorts.
Baseline Characteristics
When examining the seven different
demographic characteristics listed above, the
average age was 70 years for patients in each
cohort, with the exception of the exenatide QW
cohort where the average age was 71. The
percentage of males in each cohort ranged
between 44% (exenatide BID) and 49%
(exenatide QW). Most patients in each cohort
were covered by an HMO or PPO plan, with
significantly more exenatide QW patients
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Total sample size, n 537 3673 923 1980 1693
Gender, male (%) 49.50 46.60 44.10 45.70 47.70
Mean age, years (SD) 71 (5) 71a (4) 70a (4) 71a (4) 70a (4)
Plan type
HMO (%) 50.30 43.10 42.40 42.1 44.2
POS (%) 1.30 2.40 2.00 2.3 2.4
PPO (%) 40.00 43.40 38.10 44.6 42.0
FFS (%) 8.40 11.10 13.80 10.9 11.3
Race
White (%) 85.5 85.0 82.9 85.6 84.4
Black (%) 8.0 10.2 8.3 10.3 10.1
Hispanic (%) 3.9 1.2 0.1 1.0 1.4
Others (%) 2.6 3.6 8.7 3.2 4.1
Geographical region
South (%) 70.4 65.8 56.7 64.9 66.8
Midwest (%) 20.7 21.0 25.0 21.6 20.3
Northeast (%) 2.2 2.1 4.6 1.7 2.5
West (%) 6.7 11.1 13.8 11.8 10.4
Prescriber specialty
Endocrinologist (%) 4.1 3.6 5.0 3.0 4.4
General practitioner (%) 37.8 41.1 38.2 43.8 37.9
Internal specialist (%) 40.6 36.4 40.0 35.4 37.7
Unknown (%) 17.5 18.8 16.4 17.8 20.0
Index ﬁlled at retail pharmacy (%) 81.2 68.9a 73.8a 71.5a 65.9a
Comorbidities
Microvascular complications of diabetes (%)b 40.0 36.4 34.5a 35.2 37.9
Cardiovascular disease (%) 34.3 31.6 32.2 32.0 31.2
Dyslipidemia (%) 89.8 89.4 83.6a 88.6 90.3
Hypertension (%) 90.5 88.6 85.6a 88.7 88.4
Hypoglycemia (%) 1.3 1.1 0.9 0.9 1.2
Obesity (%) 23.5 22.5 19.0a 21.6 23.6
Renal impairment (%) 26.1 25.6 23.3 26.3 24.8
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(50.3%) on an HMO plan. Of the geographical
regions served by the health plan, the largest
representation was in the South for all five
cohorts, with the next largest representation in
the Midwest. Very small percentages of patients
in all cohorts were found in the West and
Northeast. Most of the patients in each cohort
were receiving prescriptions for a GLP-1RA from
their general practitioner or an internal
specialist, and very few received GLP-1RA
prescriptions from an endocrinologist. More
than 70% of the patients in each cohort had
their index therapy filled at a retail pharmacy,
with 81% of patients in the exenatide QW
cohort having their index GLP-1RA filled at a
retail pharmacy.
Clinical Characteristics
The overall mean DCCI scores were low












Endocrinologist visit (%) 21.4 19.2 19.5a 16.6a 22.2
Indices of general health status and resource use
Deyo–Charlson Comorbidity Index (DCCI) 1.8 (1.6) 1.7 (1.5) 1.6 (1.6) 1.7 (1.6) 1.7 (1.5)










Inpatient admission at baseline 0.18 (0.5) 0.18 (0.6) 0.15 (0.5) 0.19 (0.6) 0.16 (0.5)
Baseline anti-diabetes medications
Alpha-glucosidase inhibitors (%) 0.6 0.8 1.1 0.7 0.9
Biguanides (%) 60.1 60.8 58.8 60.8 60.9
DPP-4i (%) 28.3 17.5a 11.8a 17.8a 17.2a
Dopamine receptor agonists (%) 0.4 0.1 0.1 0.1 0.1
Meglitinides (%) 1.9 1.6 1.8 2.0 1.1
Sulfonylureas (%) 50.3 54.5 53.1 56.4a 52.3
TZDs (%) 11.9 11.5 19.0a 12.6 10.2
Insulins (%) 25.0 24.7 16.7a 23.6 26.0
Amylin analog (%) 0.4 0.1 0.2 0.2 0.1
Fixed-dose combination medications (%) 15.5 10.7a 7.8a 11.0a 10.4a
Number of other anti-diabetes medication
classes, mean (SD)
2.10 (1.1) 1.93a (1.0) 1.80 (1.1) 1.96a (1.0) 1.89a (1.1)
BID Twice daily, DCCI Deyo Charlson comorbidity index, DPP-4i depeptidyl peptidase-4 inhibitor, FFS fee for service,
HMO health maintenance organization, POS point of service, PPO preferred provider organization, QD once daily, QW
once weekly, TZD thiazolidinedione
a Denotes a signiﬁcant difference from exenatide QW cohort
b Microvascular complications of diabetes includes diabetic nephropathy, diabetic retinopathy, and diabetic peripheral
neuropathy; cardiovascular disease included atherosclerosis, stroke, myocardial infarction, unstable angina pectoris, heart
failure, percutaneous coronary intervention, and coronary artery bypass graft
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score for the exenatide QW cohort being the
highest at 1.8, and the mean DCCI score for
the exenatide BID cohort being the lowest at
1.6. When examining the additional
comorbid conditions, a large percentage of
patients in each of the five cohorts had a
diagnosis of dyslipidemia (between 84% and
90%) or hypertension (between 86% and
91%). Very few patients in any of the
cohorts had a claim for hypoglycemia (1%
or less). When looking at all conditions, the
exenatide BID cohort had significantly fewer
comorbid conditions than the exenatide QW
cohort, and the patients in the exenatide QW
cohort had similar counts of comorbid
conditions as the liraglutide QD and
liraglutide QD sub-cohorts. The general
health and resource use results showed that
the exenatide QW cohort had higher costs at
baseline ($6007) than all other cohorts and
more inpatient admissions at baseline (0.18)
than the exenatide BID (0.15) and liraglutide
QD 1.8 mg (0.16) cohorts.
After adjusting using the IPTW methods
discussed in the ‘‘Statistical Analyses’’ section
and re-computing the statistical tests for the
demographic and clinical characteristics, all
failed to generate any significant differences
between the cohorts. The results for all
remaining analyses were based on
IPTW-adjusted analyses.
Baseline Anti-diabetes Medication Use
The baseline use of anti-diabetes medications
showed that larger percentages of patients in
each cohort were prescribed biguanides
(approximately 60%) and sulfonylureas
(between 50% and 56%). Very few patients in
any of the cohorts had claims for dopamine
receptor agonists (\1%), amylin analogues
(\1%) or meglitinides (\2%). Those patients
who initiated on exenatide QW had greater
utilization of DPP-4i (28.3%) and fixed-dose
combination medications (15.5%) than all
other cohorts. The exenatide QW patients also
had more insulin use, but used fewer TZDs than
patients initiating therapy with exenatide BID.
The number of other anti-diabetes medication
classes prescribed to patients in each cohort was
approximately two. However, the exenatide
QW cohort had slightly more prescribed
classes than any of the other cohorts.
Dosage and Refill Rates
Given the variations between products,
determining the dosage for each of the cohorts
provided some insight on how these products
are used in an aged population. Table 2 shows
the mean index dose based on the index fill, the
daily dose calculation, and the rate of refills for
each cohort.
The results presented in Table 2 show that
the index dose approximated the recommended
dosing for each cohort. For the overall
Table 2 Mean index dose, daily dose and reﬁll rates for each GLP-1RA cohort: IPTW adjusted
Exenatide QW Liraglutide Exenatide BID Liraglutide 1.2 mg Liraglutide 1.8 mg
n5 537 n5 3373 n5 923 n5 1980 n5 1693
Index dose, mean (SD) 2.0 mg (0.15) 1.5 mg (0.41) 15.2 mcg (5.05) 1.3 mg (0.35) 1.7 mg (0.35)
Range [0.5–2.5] [0.3–2.5] [5.0–22.0] [0.3–2.5] [0.6–2.5]
Daily dose, mean (SD) 2.0 mg (0.17) 1.5 mg (0.38) 15.9 mcg (4.70) 1.3 mg (0.34) 1.7 mg (0.32)
Range [1.3–2.5] [0.4–2.5] [5.0–22.0] [0.4–2.5] [0.6–2.5]
Reﬁll rate, mean (SD) 3.1 (1.98)a 3.0 (1.82) 2.7 (1.89) 3.1 (1.80)b 2.7 (1.81)
Range [0.0–5.0] [0.0–5.0] [0.0–5.0] [0.0–5.0] [0.0–5.0]
BID Twice daily, GLP-1RA glucagon-like peptide-1 receptor agonist, IPTW inverse propensity treatment weighting, mcg
micrograms, mg milligrams, SD standard deviation, QW = once weekly
a Denotes signiﬁcantly different from Exenatide BID cohort
b Denotes signiﬁcantly different from Liraglutide 1.8 mg cohort
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liraglutide QD cohort, the mean index dose of
1.5 represented the weighted mean of the
liraglutide QD 1.2 mg and liraglutide QD
1.8 mg cohorts. The index dose of 15.2 for the
exenatide BID cohort represented an accurate
initial dosage since the therapy has a
recommended dosage of 10 or 20 mcg. The
index dosages found for each liraglutide QD
sub-cohort were also very close approximations
of the recommended dosage for these two
cohorts.
Whereas the index dose represented the
initial dose of the target drug, the daily dose
represented the average of the calculated daily
dose for the entirety of the post-index period. As
seen in Table 2, results for the daily dose
calculations were similar to those for index
dose.
When examining refill rates, the exenatide
QW cohort had more refills on average (3.1)
than the exenatide BID (2.7) or liraglutide QD
1.8 mg (2.7) cohorts. However, the exenatide
QW cohort had similar refill rates as the overall
liraglutide QD (3.0) and liraglutide QD 1.2 mg
(3.1) cohorts. Within the liraglutide QD
sub-cohorts, the liraglutide QD 1.2 mg cohort
had higher refill rates than the liraglutide QD
1.8 mg cohort.
Adherence
Adherence to the index therapy was computed
using the PDC. Adherence was measured for
patients who had a PDC of 80% or 90% or
greater. Figure 2a displays the percentage of
patients in each cohort who reached the 80%
and 90% PDC, while Fig. 2b shows the mean
PDC for each cohort. When examining patients
who reached an 80% PDC or better, exenatide
QW patients were significantly more adherent
to their medication (43.2%) than patients
initiating on liraglutide QD (35.0%; P\0.001),
exenatide BID (39.0%; P\0.01) or liraglutide
QD 1.8 mg (30.0%; P\0.001). While exenatide
QW patients had a slightly higher PDC at 80%
than liraglutide QD 1.2 mg patients (39.3%),
there was no significant difference between
groups (P\0.10).
The percentage of patients in each cohort
who reached a 90% PDC was smaller than those
who reached an 80% PDC (Fig. 2a). The
proportion of patients who reached a 90% or
better adherence rate was significantly higher
among patients who initiated treatment with
exenatide QW (37.24%; P\0.001) than
patients who initiated on liraglutide QD
(23.31%), exenatide BID (20.6%), liraglutide
QD 1.2 mg (26.36%) or liraglutide QD 1.8 mg
(19.73%).
Figure 2b shows the mean PDC for exenatide
QW patients (63.5%) was significantly higher
than the exenatide BID (57.7%; P\0.01) and
the liraglutide QD 1.8 mg (58.3%) patients.
However, the mean PDC was similar for the
Fig. 2 a Adherence as a function of GLP-1RA type and
dose form. Adherence measured using PDC (proportion of
days covered) at 80% and 90% for all GLP-1RAs and doses
for liraglutide QD. BID Twice daily, mg milligrams, PDC
proportion of days covered, QD once daily, QW once
weekly. b Mean adherence as a function of GLP-1RA type
and dose form
Adv Ther (2017) 34:658–673 667
exenatide QW patients and liraglutide QD
(61.5%) and liraglutide 1.2 mg (64.2%) patients.
When looking at the probability of one
cohort achieving an adherence rate of C80%,
Fig. 3 indicates that patients initiating on
exenatide BID and liraglutide QD showed a
lower probability of reaching a PDC of 80% or
better than patients who initiated on exenatide
QW. It appears that the liraglutide QD 1.8 mg
cohort drove the reduced probability. The
liraglutide QD 1.2 mg cohort also had lower
probabilities of adherence than the exenatide
QW patients. Figure 3 also shows the
contributing factors that could have
contributed to lower probabilities of adherence
for these older patients. The logistic regression
estimate for these factors is converted into a
likelihood percentage of being adherent. The
presence of baseline cardiovascular
comorbidities, insulin use, and health plan
type (HMO vs PPO) were associated with
significantly lower adherence rates in the
liraglutide QD and exenatide BID cohorts. The
other factors included in the model did not
reach significance.
Figure 4 shows the probabilities of different
patient characteristics that could have led to a
greater chance of hospitalization (all-cause
hospitalization). As with adherence, the
likelihood of an all-cause hospitalization came
from the logistic regression coefficients. An
increase in the DCCI score, presence of
Fig. 3 Multivariate logistic regression adjusted odds of
adherence during 6-month follow-up period. Contributing
factors that could lead to lower probabilities of adherence
for older patients with T2D. Adherence measured using
PDC (proportion of days covered). Exenatide QW was
used as the reference point. BID Twice daily, HMO health
maintenance organization, QD = once daily; QW = once
weekly
Fig. 4 Multivariate logistic regression adjusted odds of
hospitalization during the 6-month follow-up period.
Patient characteristics that could lead to a greater chance
of hospitalization. Examined all cause hospitalization using
exenatide QW as the reference point. aP\0.01 Deyo
charlson comorbidity index (DCCI) at baseline;
bP\0.0001 vs. no cardiovascular comorbidities at base-
line; cP\0.0001 vs. no obesity at baseline; dP\0.001 vs.
non-adherence; eP\0.05 being an HMO or fee for service
(FFS) member vs. PPO member; gP\0.05 vs West
geographical region
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baseline cardiovascular comorbidities, obesity,
and increases in age were all significantly
associated with a higher risk of being
hospitalized in the 6 months post-index period
(all P values less than 0.05). An increase of 1
point for the DCCI increased the risk of
hospitalization by 9.4%, while a 5-year age
increase was associated with a nearly 10%
increase risk of all-cause hospitalization.
However, for those patients who were
adherent to their GLP-1RA therapies, at a PDC
of C80% and C90%, the risk for all-cause
hospitalization was significantly reduced.
Other factors included in the model such as
plan type (HMO or FFS) or geographical region
did not reach significance.
DISCUSSION
The results of this study indicated that
medication adherence was different for
patients based on the individual GLP-1RA
therapy selected at treatment initiation. The
GLP-1RA-naı¨ve exenatide QW cohort patients
achieved a higher adherence rate, as measured
by PDC, than patients in the other two
GLP-1RA-naı¨ve treatment cohorts. This pattern
was similar for the two levels of PDC measured,
which were C80% and C90%. Index and daily
dosing results also showed that patients in all
GLP-1RA cohorts received the recommended
dosage based on their prescribing label. This
also held true for the two liraglutide sub-cohorts
(1.2 mg and 1.8 mg). These dosing results are
consistent with other studies that show the
appropriate treatment is being dispensed to
patients on GLP-1RAs [24].
Exenatide and liraglutide were compared, as
well as three dosage regimens (BID, QD, and
QW). The results showed that exenatide QW
had higher adherence rates (C80% and C90%)
than either liraglutide QD or exenatide BID
suggesting that the dosage regimen for
GLP-1RAs may be an important factor
contributing to higher adherence. It should be
noted that the liraglutide 1.2 mg and 1.8 mg
cohorts generated different adherence rates,
suggesting that tolerance to the drug may be
an important factor in achieving adherence to
GLP-1RAs. Other contributing factors that were
found to be associated with adherence in the
elderly population included baseline
cardiovascular comorbidities, insulin use, and
health plan type (HMO vs. PPO). A better
understanding of factors and its association
with adherence may allow for a more
personalized approach and aid in achieving
therapeutic targets.
Because these are newer treatments for
patients with T2D, information regarding
adherence is sparse, particularly for older
adults; however, there are a few previous
studies that evaluated medication adherence
for exenatide BID and liraglutide QD [25, 26].
Some of this evidence shows that there are no
differences in adherence between these two
treatments, while one study shows a
significant difference in adherence rates
[25, 26]. For example, Pelletier and colleagues
[25] found similar medication adherence rates
using a PDC calculation between exenatide BID
and liraglutide QD in the 6 months following
initiation [25]. In another retrospective study,
Malmenas and colleagues [26] found that
patients initiating therapy with exenatide BID
had significantly higher rates of adherence than
those patients initiating on liraglutide QD
1.8 mg [26].
Furthermore, a study by Johnston and
colleagues [19] examined patient adherence
rates between exenatide QW, exenatide BID,
liraglutide QD, and the liraglutide sub-cohorts
[19]. Their results showed that patients who
initiated with exenatide QW had higher
adherence rates when compared to other
GLP-1RAs. The results of the current study are
consistent with Johnston et al., and expand on
existing literature by examining how these
medications are being used by an older
population with T2D.
One possible reason for the better adherence
rates observed for exenatide QW among older
patients with T2D could be due to the
once-a-week dosage regimen. Exenatide BID
and liraglutide QD require twice- or once-daily
injections, respectively. Treatments for diabetes
require that individuals have the ability to
perform self-care tasks such as weight
management and exercise, as well as the
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self-administration of medications. Because
older adults are at increased risk for cognitive
and physical limitations, this could have a
greater impact on self-care tasks and
administration of the designated GLP-1RA as
prescribed, and therefore lead to lower
adherence [27–29]. Cognitive function is an
interesting discussion as it pertains to
adherence and to overall diabetes care in
elderly patients. There are so many factors that
could influence adherence, and it could be
inferred from the current findings (and others
about once-weekly administration) that
once-weekly administration and
predictable dosing regimen may support other
types of non-pharmaceutical patient care,
particularly in the elderly population. As a
visiting nurse, understanding the adherence of
different therapies within class could
potentially further support personalized,
targeted diabetes care. Assessing for cognitive
dysfunction and depression along with
perceived self-efficacy, coupled with the
understanding of adherence, could further
help to identify vulnerable patients and assist
with personalized care in elderly patients with
T2D. While non-adherence to the GLP-1RAs
may not be as significant for younger diabetes
patients, the dosage regimens for these
treatments could become a problem for those
with memory issues or mild physical
impairments which may limit their ability to
perform these tasks. Only having to remember a
once-weekly injection such as exenatide QW
may help aid older patients with T2D with their
adherence to their GLP-1RA. The treatment
regimen and dosing frequency should be
considered when making treatment decisions
for older patients.
Medication adherence is a growing concern
among clinicians, healthcare systems, and other
stakeholders (e.g., payers) because of mounting
evidence that non-adherence is prevalent and
associated with adverse outcomes such as more
frequent hospitalizations and higher costs of
medical care [30]. Medication non-adherence is
likely to grow as the US population ages and as
patients take more medications to treat chronic
conditions [31]. Therefore, understanding the
barriers to medication adherence, particularly
in the elderly population, will be essential [32].
The emphasis on performance measures that
reward quality based on the attainment of
treatment targets such as blood pressure, or
outcomes such as 1-year mortality after
hospitalization for conditions such as acute
myocardial infarction, reinforces the
importance of longitudinal medication
adherence. In particular, the Centers for
medicare and medicaid services (CMS) utilize
several quality measures to assess medication
adherence in patients with T2D [33]. Barriers for
optimal adherence to treatments for T2D could
be due to regimen complexity. Studies
examining the association between
anti-diabetes medication regimen complexity
and anti-diabetes medication adherence have
shown that regimens with less frequent dosing
are associated with increased adherence
[34, 35]. However, adherence to treatments
after a certain period of time is similar for
orals and injectables, so lack of adherence may
not be solely based on regimen complexity.
Previous work has shown that GLP-1RAs have
better adherence rates than insulin but lower
rates than oral treatments. Counseling patients
on the use and benefits of GLP-1RAs could also
be key in promoting lifestyle modifications and
adherence to these treatments [36].
Medication adherence also has an impact on
resource utilization in older patients, not only
for diabetes but for the other comorbidities. As
these patients age, they will require or seek out
more healthcare services and require more
hospitalizations [37]. Based on these results,
the specific GLP-1RA a patient received did not
have an impact on hospitalizations; however,
adherence to their GLP-1RA therapy resulted in
a significant reduction in risk of hospitalization.
Because of the increasing resource use, it is
important to understand the relationship of
adherence with resource utilization and also
other factors that may contribute to increased
health care resource use. In this analysis, we also
identified different patient characteristics that
were associated with a greater chance of
hospitalization, which may provide further
understanding in identifying high-risk patients
with diabetes and supporting patient-centered,
personalized care.
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Limitations
This study has several important limitations
that should be considered when interpreting
the current findings. Administrative claims data
are subject to potential coding error and are not
collected for research purposes. Such errors may
introduce measurement error with respect to
ICD-9-CM–based variables. Administrative
claims data also have certain limitations
regarding the type and amount of data
available. The representations of provider
specialties are not always captured well on
medical claims, therefore making it difficult to
examine how a visit with a diabetes educator or
nurse or who prescribed a specialty treatment
could influence outcomes. Claims data can also
constrain the ability to look at social conditions
that might influence outcomes. Not all data
points are available for patients, such as HbA1c
levels, which could be used to further show the
importance of an outcome.
Findings from the study may not be
generalizable to the entire US population,
including the populations of individuals who
are uninsured or those who have insurance
coverage through Medicaid or the military.
Most plans are regional in nature and
therefore will show larger patient populations
in certain areas of the United States. The
database used for this study has broader
coverage in the South and Midwest than the
West or Northeast which caused the disparity in
geographic representation. Although we
classified patients treated with liraglutide into
1.2 mg or 1.8 mg on the basis of days supplied
and metric quantity recorded on the pharmacy
claims, liraglutide is delivered in a
self-adjustable prefilled dosing pen, and it is
therefore possible that patients may have
self-administered more or less liraglutide than
would be indicated for given prescription’s days
supplied and metric quantity. Despite our
attempt to control for confounding through
the use of multivariable logistic regression,
observational analyses such as the present
study may be subject to residual confounding
due to unmeasured variables such as disease
severity. Finally, if physicians selectively
prescribe a once-weekly regimen because of
anticipated medication non-adherence, such
channeling bias may have led to worse than
expected adherence among exenatide QW
patients.
CONCLUSION
Medication adherence is an important factor in
the treatment of chronic conditions like
diabetes. It is particularly important for older
patients diagnosed with diabetes in order to
prevent disease complications. GLP-1RA
therapies have shown good efficacy results in
patients with diabetes, yet there is limited
patient adherence and dosing frequency
impact information, particularly for elderly
patients with diabetes. Further research should
be pursued to determine the characteristics of
the patients with high and low medication
adherence to determine the most appropriate
treatment plan.
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